A bitter pill: Price of biologic drugs often too high for poor, ill seniors who need them
“For people with serious diseases like cancer and arthritis, these drugs are often their last hope,” said Schumer, who plans another try when the bill hits the Senate floor. “To not price them fairly, at the behest of the brand-name drug industry, is outrageous.”
Consumer Groups Threaten To Withdraw Biologics Bill Support
“In all frankness, we cannot be supportive of any generic biologics legislation that would be an empty promise to the Americans we represent and serve,” the letter said. The letter, signed by AARP, the Consumers Union, the Coalition for a Competitive Pharmaceutical Market and other groups, was sent to House Energy and Commerce Committee Chairman Rep. Henry Waxman, D.-Calif.
The letter, also signed by the Generic Pharmaceutical Association, urges Congress to “reject the fatally flawed” biologics legislation proposed by Rep. Anna Eshoo, D.-Calif., and criticizes biologics legislation passed in a Senate committee earlier this week. Eshoo wasn’t immediately available to comment.
For some background on the battle of the exclusivity period of biologics that is currently taking place in the U.S. Congress (thing are currently moving in favor of the Biotech and pharmaceutical industries), take a look at my post of last week: The Battle Over Biologics.